Physician profile
Gregory L Freeman
NPI 1871600866
$1,125.65
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $119 · 2021: $294 · 2022: $50.81 · 2023: $32.83 · 2024: $164 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $226.83 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $193.37 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $172.65 | 2019-2024 | |
| Esperion Therapeutics, INC. | $133.15 | 2021 | |
| Boston Scientific Corporation | $120.24 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $77.10 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $61.84 | 2019-2020 | |
| Amgen INC. | $60.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.87 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.